Skip to content

Category Archives: Pharmaceutical

FDA Delays Approval Of Bone Loss Treatment Drug Prolia

23-Oct-09

After Amgen Inc. posted earnings that beat expectations, the U.S. Food & Drug Administration (FDA) quickly put a stop to the celebration, delaying the approval of its next potential best-seller – Prolia. The FDA requested that further testing be conducted on the drug Prolia, before it could approve the drug for treating bone loss. It [...]

Also filed in | Tagged , , , , , | Comments (0) »

SciClone Pharmaceuticals Gets Thumbs Down

06-Oct-09

Last Friday, SciClone Pharmaceuticals Inc. received a thumbs down from a data safety monitoring committee, which recommended that the company stop its Phase II trial of a potential treatment of late-stage pancreatic cancer. The drug being reviewed was RP101, and was in its mid-stage of testing. Usually, studies for pancreatic cancer are severely hampered due [...]

Also filed in | Tagged , , | Comments (0) »

Johnson & Johnson Buys Stake In Elan

03-Jul-09

Johnson & Johnson is looking to dominate yet another pharmaceutical market. This time around it has bought an 18.4% stake in Irish drugmaker Elan Corp, with plans to develop its experimental drug program for the treatment of Alzheimer’s disease. This deal will also benefit Elan, which has come under fire lately from its shareholders to [...]

Also filed in | Tagged , , | Comments (0) »

Clinical Trial Shows Brilinta More Effective Than Plavix

12-May-09

The pivotal clinical trial of AstraZeneca’s experimental heart drug Brilinta kicked its rival drug Plavix out of the competition. The test revealed that Brilinta is more effective than Plavix in protecting high-risk patients from heart attacks as well as strokes. AstraZeneca is on schedule to submit the drug for regulatory approval in late 2009. If [...]

Also filed in | Tagged , , , | Comments (0) »